URGN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 108916 min ago

@ $19.19

Išleistas: 13 vas. 2024 @ 18:02

Grąža: -26.27%

Ankstesnis signalas: vas. 12 - 22:11

Ankstesnis signalas: Pirkimas

Grąža: -0.20 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases...

Stats
Šios dienos apimtis	135 619
Vidutinė apimtis	364 868
Rinkos kapitalizacija	482.83M
EPS	$0 ( 2024-03-21 )
Kita pelno data	( $-0.930 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.99
ATR14	$0.0290 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Schoenberg Mark	Sell	12 000	Ordinary Shares
2024-01-31	Kim Dong	Buy	3 333	Ordinary Shares
2022-03-25	Kim Dong	Buy	20 000	Stock Option (right to buy)
2024-02-01	Smith Jason Drew	Sell	3 328	Ordinary Shares
2024-02-01	Smith Jason Drew	Sell	1 248	Ordinary Shares

INSIDER POWER
58.85
Last 96 transactions
Buy: 1 308 776 \| Sell: 407 960

Tūris Koreliacija

Ilgas: 0.26 (neutral)

Trumpas: -0.02 (neutral)

Signal:(62.511) Neutral

Urogen Pharma Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVAC	0.916
GOODM	0.907
TLGT	0.891
MTSL	0.871
NSTS	0.866
TTWO	0.86
LUNG	0.851
PAIC	0.851
RMNI	0.845
RCM	0.833

10 Labiausiai neigiamai susiję koreliacijos
LWAC	-0.955
SRAC	-0.919
AMRB	-0.902
LMRKN	-0.889
NETE	-0.881
KNSA	-0.847
UTHR	-0.847
RAVN	-0.84
OFS	-0.831
TECH	-0.828

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Urogen Pharma Ltd Koreliacija - Valiuta/Žaliavos

-0.37
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.54
( weak negative )

0.05
( neutral )

-0.06
( neutral )

Urogen Pharma Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	$82.71M
Bruto pelnas:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2023
Pajamos:	$82.71M
Bruto pelnas:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2022
Pajamos:	$64.36M
Bruto pelnas:	$56.70M (88.11 %)
EPS:	$-4.79

FY	2021
Pajamos:	$48.04M
Bruto pelnas:	$42.89M (89.27 %)
EPS:	$-4.96

Financial Reports:

No articles found.

Urogen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.